Psychedelic-Assisted Therapy in Canada: The 2025 Rules Explained

Introduction

Psychedelic-assisted therapy has moved from the fringes of research into a serious clinical and commercial conversation in Canada. Clinics want to offer it. Sponsors want to study it. Investors want to back it. And patients living with treatment-resistant conditions want access to it.

The challenge is that the rules are easy to misread. Psilocybin and MDMA are still controlled substances. There is no approved psychedelic drug product on the Canadian market for general prescribing. What does exist is a set of narrow, tightly controlled legal pathways, each with its own paperwork, security expectations, and review timelines.

This guide explains how psychedelic-assisted therapy is actually regulated in Canada in 2025. We cover the three legal pathways, the recent Federal Court ruling that is reshaping practitioner training, the controlled-substance scheduling you need to understand, and the practical compliance steps that separate a defensible application from a rejected one. It is written for clinics, research sponsors, prospective controlled-substance dealers, and investors who need an accurate picture before committing time and capital.

Executive Summary

For those who want the short version, here are the key points.

• Psilocybin, psilocin, and MDMA remain controlled substances in Canada. Activities involving them are prohibited unless Health Canada specifically authorizes them.
• There are three legal pathways for legitimate access: authorized clinical trials, the Special Access Program (SAP), and Section 56 exemptions under the Controlled Drugs and Substances Act (CDSA).
• The SAP reopened to restricted drugs such as psilocybin and MDMA on January 5, 2022, allowing practitioners to request access for patients with serious or life-threatening conditions when other options have been exhausted.
• Health Canada has issued a subsection 56(1) class exemption so that practitioners, pharmacists, hospitals, and licensed dealers can carry out the activities tied to an SAP authorization without each person applying for an individual exemption.
• In Toth v. Canada, 2025 FCA 119 (June 25, 2025), the Federal Court of Appeal found that Health Canada had not adequately explained why it reversed its position on experiential psilocybin training for practitioners, and it sent those exemption requests back for redetermination.
• Anyone planning to possess, produce, import, or distribute these substances at scale will likely need a CDSA dealer's licence, which brings security, record-keeping, and inspection obligations.

The opportunity is real, but it is built on disciplined regulatory work. The sections below explain each piece.

The Three Legal Pathways at a Glance

What is the legal route to psychedelics in Canada? There is no general prescription pathway. Legitimate access flows through one of three mechanisms, each suited to a different purpose. Clinical trials are for building evidence. The Special Access Program is for individual patients in serious need. Section 56 exemptions are a flexible tool used for research and, historically, for practitioner training.

The table below compares the three.

Each pathway is explained in detail below, including what it does well and where applicants commonly run into trouble.

Pathway 1: Clinical Trials

What is it? A clinical trial is the formal, evidence-building route. A sponsor works with a qualified investigator to study a psychedelic substance under a controlled protocol. This is the pathway Health Canada most clearly prefers, because it is designed to answer the questions that approval ultimately depends on: does it work, for whom, and how safely.

Why does it matter? Clinical trials are the only pathway that can lead to a future approved drug product. They are also the most scrutinized. To conduct research with psilocybin, a Clinical Trial Application (CTA) must be submitted under Part J of the Food and Drug Regulations, and Health Canada must issue a No Objection Letter before the trial can proceed. The qualified investigator typically also needs a letter of endorsement from their affiliated institution.

What should companies do? Treat the CTA as a complete evidence package, not a form. Health Canada reviews the protocol, the investigator's brochure, the quality and manufacturing information for the drug, and the safety monitoring plan. Sponsors who succeed tend to invest early in chemistry, manufacturing, and controls (CMC) data, in a defensible safety plan, and in the controlled-substance logistics that sit alongside the clinical work.

How does it affect compliance? A trial involving a controlled substance triggers obligations beyond the clinical protocol. The site needs secure storage, accurate records of every gram received and administered, and clear accountability for any unused product. A recent class exemption also addresses at-home administration of MDMA or psilocybin by participants enrolled in an authorized trial, which carries its own conditions. Getting the controlled-substance side wrong can stall an otherwise sound study.

Pathway 2: The Special Access Program (SAP)

What is it? The Special Access Program lets a practitioner request a drug that is not otherwise available in Canada for a specific patient. On January 5, 2022, Health Canada published final regulations that reversed a 2013 change and once again allowed practitioners to request restricted drugs, including psilocybin and MDMA, through the SAP.

Why does it matter? The SAP is the main route for individual patient access today. It is meant for patients with serious or life-threatening conditions where other therapies have failed, are unsuitable, or are not available, and where there is enough evidence to support the requested use for that patient's situation. It is not a shortcut around clinical trials, and it is not a guarantee. Each request is assessed case by case.

What should companies and clinics do? Build the request around the patient's clinical history and the supporting evidence, not around enthusiasm for the therapy. A strong SAP request clearly documents the diagnosis, the treatments already tried, why they failed or are unsuitable, and the rationale for the requested drug. The practitioner also has to confirm a willing supplier, because the manufacturer must agree to provide the drug. The SAP cannot compel a manufacturer to supply it.

How does it affect compliance? To smooth the activities that follow an authorization, Health Canada issued a subsection 56(1) class exemption covering practitioners, pharmacists, persons in charge of a hospital, hospital employees, and licensed dealers conducting activities with psilocybin and MDMA in relation to an SAP authorization. The class exemption removes the need for each party to seek an individual exemption, but it does not approve the request itself, and it comes with conditions that everyone in the chain must follow.

One practical note for 2025: industry observers have reported that SAP approvals for psychedelic-assisted therapy have become slower and less frequent than in prior years. That makes the quality of each request matter even more.

Pathway 3: Section 56 Exemptions

What is it? Section 56 of the CDSA gives the Minister of Health discretion to exempt a person or a class of people from the application of the Act when it is in the public interest, for medical or scientific reasons. It is the most flexible tool in the system, which is also why it has been the most contested.

Why does it matter? Section 56 exemptions have been used for research access and, importantly, for experiential training, where practitioners take psilocybin themselves so they can better support patients during sessions. A qualified investigator who needs a controlled substance for research that includes administering it to humans in a clinical trial generally requires a subsection 56(1) exemption alongside the other approvals.

What should applicants do? Approach a Section 56 request as a reasoned, evidence-supported argument addressed to a decision-maker who has wide discretion. The strongest applications anticipate the questions Health Canada will ask: why is an exemption necessary, why is a clinical trial not the right fit for this purpose, and how will risk be managed. The 2025 court ruling discussed below shows how much the reasoning, on both sides, matters.

How does it affect compliance? Because exemptions are discretionary, they can shift with policy. That uncertainty is a planning risk. Organizations that rely on Section 56 access should document everything, monitor policy signals closely, and avoid building a business model that depends on a single discretionary decision staying in place.

The 2025 Federal Court Ruling: What Changed

What happened? In Toth v. Canada (Mental Health and Addictions), 2025 FCA 119, released on June 25, 2025, the Federal Court of Appeal sided with a group of health-care practitioners who had been refused Section 56 exemptions to use psilocybin for experiential training. The case grew out of requests connected to the patient advocacy organization TheraPsil and dozens of practitioners.

Why does it matter? The court did not order Health Canada to grant the exemptions. Instead, it found that Health Canada had failed to explain a significant shift in its own position. In 2020, the then Minister granted exemptions to 19 practitioners for experiential training. In 2022, near-identical requests were refused. The court held that the Minister cannot make such an abrupt change without a transparent explanation, and it sent the requests back to the Minister for redetermination in line with the court's reasons.

What should organizations take from it? Two things. First, the decision reinforces that Canadian regulators are expected to be consistent and to give reasons, which is encouraging for applicants who feel decisions have been arbitrary. Second, it is a reminder that the law in this area is still being shaped through litigation. A favourable ruling on process does not by itself create a stable training pathway. The practical outcome depends on how Health Canada responds on redetermination.

How does it affect compliance planning? If your model assumes ready access to experiential training exemptions, treat that assumption as provisional. Build contingencies, keep careful records of any applications and correspondence, and watch for Health Canada's next steps before committing significant resources.

Controlled-Substance Scheduling You Need to Know

Compliance starts with knowing exactly what you are handling. Psychedelics are not treated identically under Canadian law, and the scheduling drives many downstream obligations.

Both substances are "restricted drugs," which means access for legitimate purposes runs through the pathways above plus, where applicable, a dealer's licence. The difference in CDSA schedule is one reason MDMA work often draws heightened attention to security and accountability.

The CDSA Dealer's Licence and Security Requirements

What is it? A Controlled Drugs and Substances dealer's licence authorizes an organization to possess a controlled substance and to carry out specified activities, which can include production, packaging, sale, transportation, laboratory analysis, research and development, clinical studies, import and export, or distribution under the Special Access Program. Many organizations planning to handle psilocybin or MDMA at any meaningful scale will need one.

Why does it matter? The dealer's licence is where regulatory ambition meets operational reality. Health Canada's Office of Controlled Substances will only issue a licence after reviewing a complete application package and, in most cases, inspecting the facility to confirm it meets the security and compliance requirements of the CDSA and its regulations. The Office of Controlled Substances aims to decide on new dealer's licence applications within 270 days of receiving a complete application, so timelines should be planned in quarters, not weeks.

What should organizations do? Prepare the facility and the paperwork together. A dealer's licence application is judged on physical security, personnel security clearances, record-keeping systems, standard operating procedures, and the qualifications of the people responsible. The most common reason for delay is an incomplete or inconsistent package that triggers rounds of questions.

How does it affect compliance? A licence is the beginning of an obligation, not the end of a process. Licence holders must maintain security, keep precise inventory records, report as required, and stay inspection-ready at all times. Building those systems before the inspection, rather than after a finding, is what keeps a programme operating.

Compliance Checklist for Psychedelic Programmes

Use this checklist as a starting point when scoping a clinical, treatment, or research programme involving psilocybin or MDMA in Canada.

• Confirm your pathway. Decide whether your purpose fits a clinical trial, the SAP, or a Section 56 exemption, and document why.
• Verify scheduling and status. Confirm the CDSA schedule and restricted-drug status for each substance you will handle.
• Secure your supply. For SAP requests, confirm a willing manufacturer before you apply.
• Build the evidence file. For trials and SAP requests, assemble clinical rationale, prior treatments, and supporting literature.
• Plan controlled-substance logistics. Address secure storage, transport, reconciliation, and disposal from day one.
• Assess licence needs. Determine whether a CDSA dealer's licence is required and budget for the review timeline.
• Prepare for inspection. Put security, SOPs, training records, and personnel clearances in place before, not after.
• Monitor policy and case law. Track Health Canada notices and decisions such as Toth v. Canada that can shift the landscape.
• Document everything. Keep complete records of applications, correspondence, and decisions.

Common Mistakes to Avoid

Even well-funded organizations stumble on the same issues. These are the ones we see most often.

• Treating the SAP as a routine prescription route. It is a case-by-case program for serious conditions, not a general access channel.
• Underestimating timelines. A dealer's licence review can run up to 270 days, and that is from the date the application is complete.
• Ignoring supplier agreements. An SAP request can fail simply because no manufacturer has agreed to provide the drug.
• Confusing the pathways. Mixing up what a clinical trial, an SAP request, and a Section 56 exemption each do leads to applications that ask the wrong body for the wrong thing.
• Building on discretionary decisions. Relying on exemptions that can change with policy, without a contingency plan, is a structural risk.
• Leaving security and records until the inspection. Weak documentation and physical security are among the most common reasons applications stall.

Frequently Asked Questions

Is psychedelic-assisted therapy legal in Canada?

There is no approved psychedelic drug product for general prescribing, but legitimate access is possible through three pathways: authorized clinical trials, the Special Access Program, and Section 56 exemptions under the CDSA. Each requires specific Health Canada authorization.

Can a doctor prescribe psilocybin in Canada?

Not as an ordinary prescription. A practitioner can request access for an individual patient through the Special Access Program when the patient has a serious or life-threatening condition and other options have been exhausted, but Health Canada assesses each request individually.

What is the Special Access Program class exemption for psilocybin and MDMA?

It is a subsection 56(1) class exemption that lets practitioners, pharmacists, hospitals, and licensed dealers carry out the activities connected to an SAP authorization without each applying for a separate exemption. It does not approve the underlying request.

What did the 2025 Federal Court ruling decide?

In Toth v. Canada, 2025 FCA 119, the Federal Court of Appeal found that Health Canada had not explained why it reversed its earlier position on experiential psilocybin training for practitioners. It sent those exemption requests back for redetermination rather than ordering them granted.

Do I need a dealer's licence to handle psilocybin or MDMA?

In most cases where you will possess, produce, import, or distribute these substances at scale, yes. A CDSA dealer's licence is issued by Health Canada's Office of Controlled Substances after a full application review and facility inspection.

How long does a CDSA dealer's licence take?

Health Canada's Office of Controlled Substances aims to issue a decision on a new dealer's licence application within 270 days of receiving a complete application.

How MFLRC Can Help

Psychedelics sit at the intersection of controlled-substance law, quality systems, and clinical strategy. That is exactly where MFLRC works. As a Canadian regulatory consulting firm with deep experience across controlled drugs, cannabis, pharmaceuticals, and the emerging psychedelics space, we help organizations move through these pathways with discipline rather than guesswork.

We support clients with:

• SAP request preparation, including the clinical rationale, evidence file, and supplier confirmation that a strong request depends on.
• CDSA dealer's licence applications, from facility security planning and SOPs through personnel clearances and inspection readiness, delivered through our regulatory affairs and licensing practice.
• Clinical-trial risk-management measures, including controlled-substance handling, storage, and reconciliation that sit alongside your protocol.
• Quality systems and SOP development through our quality assurance services, so your documentation holds up under scrutiny.
• Gap assessments and mock inspections through our audit services, so you find the weaknesses before Health Canada does.

Need help with regulatory compliance for a psychedelics programme? Contact MFLRC for expert guidance tailored to your business, or send us a question and we will respond within one business day.

Conclusion

Psychedelic-assisted therapy in Canada is legal in narrow, well-defined circumstances, and the framework is still maturing. The three pathways, clinical trials, the Special Access Program, and Section 56 exemptions, each serve a distinct purpose, and choosing the right one is the first real decision an organization makes. The 2025 Federal Court ruling in Toth v. Canada is a signal that regulators will be held to a standard of consistency and transparency, but it is not a finished pathway. The organizations that succeed will be the ones that respect the controlled-substance fundamentals, prepare complete and defensible files, and plan for review timelines measured in months.

The market is emerging, the rules are exacting, and the cost of a weak application is real. With the right regulatory strategy, responsible access and commercialization are achievable. MFLRC helps you get there with confidence.

Sources and References

• Health Canada, Notice to stakeholders: Requests to the Special Access Program (SAP) involving psychedelic-assisted psychotherapy.
• Health Canada, Subsection 56(1) class exemption for practitioners, agents, pharmacists, persons in charge of a hospital, hospital employees, and licensed dealers to conduct activities with psilocybin and MDMA in relation to a special access program authorization.
• Health Canada, Notice to Stakeholders: Clarification of Requirements under the Food and Drug Regulations and the Controlled Drugs and Substances Act When Conducting Clinical Research with Psilocybin.
• Health Canada, Subsection 56(1) class exemption for participants enrolled in an authorized clinical trial involving at-home administration of MDMA or psilocybin.
• Health Canada, Psilocybin and psilocin (Magic mushrooms).
• Toth v. Canada (Mental Health and Addictions), 2025 FCA 119 (Federal Court of Appeal, June 25, 2025). Coverage: CBC News.